Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
155.01
-1.13 (-0.72%)
At close: Jul 24, 2026, 4:00 PM EDT
155.00
-0.01 (-0.01%)
After-hours: Jul 24, 2026, 7:54 PM EDT
Novartis AG Revenue
Novartis AG had revenue of $14.95B in the quarter ending June 30, 2026, with 0.78% growth. This brings the company's revenue in the last twelve months to $56.69B, up 2.73% year-over-year. In the year 2025, Novartis AG had annual revenue of $56.67B with 9.57% growth.
Revenue (ttm)
$56.69B
Revenue Growth
+2.73%
P/S Ratio
5.21
Revenue / Employee
$753,225
Employees
75,267
Market Cap
295.30B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.67B | 4.95B | 9.57% |
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | 46.10B | 2.70B | 6.21% |
| Dec 31, 2017 | 43.40B | -6.03B | -12.20% |
| Dec 31, 2016 | 49.44B | -951.00M | -1.89% |
| Dec 31, 2015 | 50.39B | -3.25B | -6.05% |
| Dec 31, 2014 | 53.63B | 918.00M | 1.74% |
| Dec 31, 2013 | 52.72B | 745.00M | 1.43% |
| Dec 31, 2012 | 51.97B | -7.40B | -12.47% |
| Dec 31, 2011 | 59.38B | 7.81B | 15.15% |
| Dec 31, 2010 | 51.56B | 6.46B | 14.32% |
| Dec 31, 2009 | 45.10B | 2.52B | 5.92% |
| Dec 31, 2008 | 42.58B | 3.64B | 9.34% |
| Dec 31, 2007 | 38.95B | 3.84B | 10.94% |
| Dec 31, 2006 | 35.11B | 5.35B | 17.99% |
| Dec 31, 2005 | 29.75B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 97.93B |
| Merck & Co. | 65.77B |
| Pfizer | 63.32B |
| AbbVie | 62.82B |
| AstraZeneca | 60.44B |
| Sanofi | 54.60B |
| Novo Nordisk | 50.57B |
| Bristol-Myers Squibb Company | 48.48B |
NVS News
- 3 days ago - Novartis price target raised to CHF 142 from CHF 132 at Citi - TheFly
- 4 days ago - Company News for July 22, 2026 - Nasdaq
- 4 days ago - Novartis (NVS) Q2 2026 Earnings Call Transcript - The Motley Fool
- 4 days ago - Novartis (NVS) Exceeds Expectations with Strong Half-Year Results - GuruFocus
- 5 days ago - Novartis CEO Vas Narasimhan on Q2 earnings beat - CNBC
- 5 days ago - Watch CNBC's full interview with Novartis CEO Vas Narasimhan - CNBC
- 5 days ago - Novartis (NVS) Returned to Sales Growth in Q2, but the Patent-Cliff Math Still Runs the Story - AlphaStreet
- 5 days ago - Novartis Q2 Earnings Call Highlights - MarketBeat